Pharming Group Announces First Patient Dosed in Phase II Clinical Trial of Leniolisib for Common Variable Immunodeficiency (CVID) with Immune Dysregulation

Pharming Group N.V. announced that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency patients with immune dysregulation.